Get the Stockscreener App
24.13
2.78%
-0.69
After Hours:
24.13
Septerna Inc stock is traded at $24.13, with a volume of 298.69K.
It is down -2.78% in the last 24 hours and down -4.17% over the past month.
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
See More
Previous Close:
$24.82
Open:
$25
24h Volume:
298.69K
Relative Volume:
0.94
Market Cap:
$1.08B
Revenue:
$45.95M
Net Income/Loss:
$-48.88M
P/E Ratio:
-21.68
EPS:
-1.1129
Net Cash Flow:
$109.67M
1W Performance:
-0.66%
1M Performance:
-4.17%
6M Performance:
+26.14%
1Y Performance:
+237.01%
1-Day Range:
$23.29
$25.25
1-Week Range:
$22.78
$25.25
52-Week Range:
$6.415
$32.63
Septerna Inc Stock (SEPN) Company Profile
Name
Septerna Inc
Sector
Industry
Phone
650-338-3533
Address
250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO
Compare SEPN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SEPN
Septerna Inc
|
24.13 | 1.12B | 45.95M | -48.88M | 109.67M | -1.1129 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Septerna Inc Stock (SEPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-25 | Initiated | Raymond James | Strong Buy |
| Dec-15-25 | Initiated | Truist | Buy |
| Nov-14-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-23-25 | Initiated | H.C. Wainwright | Buy |
| Feb-18-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-19-24 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-19-24 | Initiated | JP Morgan | Overweight |
| Nov-19-24 | Initiated | TD Cowen | Buy |
| Nov-19-24 | Initiated | Wells Fargo | Overweight |
View All
Septerna Inc Stock (SEPN) Latest News
Septerna to Present at Bank of America Securities Health Care Conference - The Manila Times
Septerna, Inc. ($SEPN) CEO 2025 Pay Revealed - Quiver Quantitative
Stifel Maintains Septerna(SEPN.US) With Buy Rating, Maintains Target Price $43 - Moomoo
Septerna (NASDAQ:SEPN) Now Covered by Stifel Nicolaus - MarketBeat
Septerna, Inc. (NASDAQ:SEPN) Sees Significant Growth in Short Interest - MarketBeat
Stifel Initiates Septerna(SEPN.US) With Buy Rating, Announces Target Price $43 - Moomoo
Septerna (NASDAQ: SEPN) details 2026 vote on directors and auditor - Stock Titan
Septerna, Inc. (SEPN) reports Q4 loss, tops revenue estimates - MSN
Septerna (SEPN) price target increased by 34.39% to 46.41 - MSN
Are Options Traders Betting on a Big Move in Septerna Stock? - MSN
Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Septerna - MSN
Top Executives at Septerna, Inc. Make Bold Stock Purchases! - TipRanks
SEPN (Septerna Inc.) shares rise 7.46 percent after Q4 2025 loss lands narrower than consensus analyst estimates. - Xã Thanh Hà
Is Septerna (SEPN) Quietly Redefining Its GPCR Strategy With This First-in-Human SEP-479 Trial? - Sahm
Analysts Offer Insights on Technology Companies: Vicor (VICR), Ceragon Networks (CRNT) and Septerna, Inc. (SEPN) - The Globe and Mail
Truist Financial Maintains Septerna(SEPN.US) With Buy Rating - Moomoo
Septerna, Inc. (NASDAQ:SEPN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Septerna (NASDAQ:SEPN) COO Elizabeth Bhatt Sells 4,000 Shares - MarketBeat
Septerna Inc (SEPN) president and COO sells $97k in stock - Investing.com
[Form 4] Septerna, Inc. Insider Trading Activity - Stock Titan
Assessing Septerna (SEPN) Valuation After First Dosing In SEP-479 Phase 1 Trial - Sahm
SEPN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
Septerna: Advancing GPCR Pipeline and Strategic Partnerships Support Buy Rating and $40 Price Target - TipRanks
Is Septerna (SEPN) Using Its First PTH1R Trial To Redefine Its GPCR Strategy? - Sahm
HC Wainwright Reiterates Buy Rating for Septerna (NASDAQ:SEPN) - MarketBeat
H.C. Wainwright reiterates Septerna stock rating on trial start - Investing.com UK
H.C. Wainwright reiterates Septerna stock rating on trial start By Investing.com - Investing.com South Africa
Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism - Exchange Bitget
SEPTERNA INCPHASE 1 TRIAL DATA EXPECTED IN LATE 2026 OR EARLY 2027 - Moomoo
Septerna doses first patient in SEP-479 hypoparathyroidism trial By Investing.com - Investing.com Australia
Septerna doses first patients in SEP-479 trial - TipRanks
Insider Buy: Is Septerna Inc part of any ETF2026 Sector Review & Risk Controlled Stock Alerts - baoquankhu1.vn
Septerna (SEPN) Initiates Phase 1 Trial for Hypoparathyroidism T - GuruFocus
Movement Recap: Will Septerna Inc benefit from current market trendsWeekly Loss Report & Accurate Buy Signal Notifications - baoquankhu1.vn
Septerna Begins Phase 1 Clinical Trial of SEP-479, an Oral PTH1R Agonist, for Hypoparathyroidism Treatment – Data Expected Late 2026/Early 2027 1 - Minichart
Septerna Begins Phase 1 Trial of Oral SEP-479 - TipRanks
Septerna doses first patient in SEP-479 hypoparathyroidism trial - Investing.com
Septerna begins Phase 1 trial of oral PTH1R agonist SEP-479; Phase 1 data expected late 2026–early 2027 - TradingView
Septerna (Nasdaq: SEPN) begins Phase 1 trial of SEP-479 for hypoparathyroidism - Stock Titan
Septerna starts human testing of an oral drug for a lifelong disorder - Stock Titan
Septerna Inc Stock (SEPN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):